Navigation Links
Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
Date:2/28/2008

GRAND RAPIDS, Mich., Feb. 28 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today announced it is one of the first laboratories in the nation to offer a new, FDA-approved test that will aid in the treatment of metastatic prostate cancer.

The CMM (http://www.cmmdx.org) is offering the CellSearch(TM) System from Veridex (http://www.veridex.com) to physicians as a vital new tool in managing patients with metastatic prostate cancer (MPC). The CMM made CellSearch testing services available to physicians last year to help inform treatment of metastatic breast and colorectal cancer.

"This newest addition to our cutting-edge menu of diagnostic services gives physicians another tool for better managing their patients' cancer, this time prostate cancer," said CMM Executive Director Dr. Daniel H. Farkas. "In just one year, the CMM has made available to this community tests that detect and manage breast, colorectal and prostate cancers in a more proactive and efficient way than has ever been possible. It's exciting and we're pleased to serve as a unique medical resource."

The CellSearch System identifies and counts circulating tumor cells (CTCs) in a blood sample to predict progression-free and overall-survival in patients, and can do so earlier than the current standard of care. Testing for CTCs with the CellSearch System, in conjunction with other clinical methods for monitoring, can help physicians assess disease progression, thereby guiding more informed care decisions earlier.

The CellSearch System is the first diagnostic test to automatically identify and count CTCs, cancer cells that detach from solid tumors and enter the bloodstream. The system's specificity, sensitivity and reproducibility allow assessment of CTCs as early as the first cycle of treatment to help evaluate disease progression sooner.

According to the American Cancer Society (ACS), prostate cancer is the most common type of cancer found in American men, other than skin cancer. The ACS estimates that there will be about 186,320 new cases of prostate cancer in the U.S. this year, and about 28,660 men will die as a result. MPC occurs when tumor cells spread to other locations in the body and grow. Although there are several options for the treatment of MPC, oncologists often have to wait months before they can determine if a specific treatment has been beneficial to the patient.

The CellSearch System, which is distributed by Veridex, a Johnson & Johnson company, was cleared by the FDA in January 2004 as an in vitro diagnostic test to aid in the identifying and counting of CTCs in a blood sample. Pricing for the test is $495, and is covered by most insurance providers. Physicians interested in obtaining more information may contact CMM directly at 616-391-4330 or visit http://www.cmmdx.org/physicians.

About the CMM

The Center for Molecular Medicine, a joint venture between Grand Rapids, Mich.-based Spectrum Health and Van Andel Institute (VAI), brings West Michigan a cutting-edge laboratory that will aid in early diagnoses and enhance personalized medicine. It offers 21st century molecular technologies for investigation of complex diseases like cancer, heart disease, mental illness and other conditions at the DNA, RNA and protein levels. The Center brings new and increased opportunities for diagnostics and pharmaceutical companies to conduct trials in a world-class medical and clinical research environment. For more information, visit http://www.cmmdx.org.


'/>"/>
SOURCE The Center for Molecular Medicine
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
2. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
3. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
4. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
5. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
8. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
9. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
10. Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research
11. Beaumont Technology Usability Center To Offer Training For Medical Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):